Literature DB >> 10828833

Increased expression of the mRNA encoding the somatostatin receptor subtype five in human colorectal adenocarcinoma.

V Vuaroqueaux1, A Dutour, N Bourhim, L Ouafik, G Monges, N Briard, N Sauze, C Oliver, M Grino.   

Abstract

Numerous studies have suggested that the antiproliferative potency of somatostatin (SS) analogues may be an efficient tool to improve the prognosis of colorectal cancer. In order to facilitate current efforts to design potent antitumour SS analogues, we studied the distribution of human SS receptors (hsst1-5) mRNAs in a large set of tumoural and normal colonic tissues. Localisation of hsst1-5 mRNAs in normal and tumoural tissues was performed by in situ hybridisation using radioactive antisense or sense riboprobes. Semi-quantitative analysis of hsst5 mRNA was performed using a computerised image analysis system. Hsst binding sites were characterised by studying the relative potency of SS14, SS28 or SS analogues in displacing [(125)I]Tyr degrees -d-Trp(8)-SS14 bound to HT29-D4 cells. Hsst5 mRNA was by far the most expressed subtype in both normal and transformed epithelial cells as well as in the HT29-D4 cell line. An increased expression of hsst5 mRNA was found in tumours. Hsst1 mRNA was expressed preferentially as clusters in immune cells in lamina propria and in stroma close to the tumour. A low expression of hsst4, hsst3 and hsst2 was seen in normal and tumoural tissue. In HT29-D4, binding experiments with SS14 demonstrated the existence of one SS binding class (K(d)=524 nM, B(max)=1fmol/10(6 )cells). In competition binding studies, SS28 and BIM23268 (an analogue that shows preferential specificity towards hsst5) effectively inhibited binding of [(125)I]Tyr degrees -d-Trp(8)-SS14 (IC(50)=15 and 157 nM respectively), while BIM23197 (an analogue that shows preferential affinity for hsst2) was ineffective. Our results show a high expression of hsst5 mRNA in human tumoural colonic tissue, while hsst5 protein is the predominant hsst protein subtype in a tumoural colonic cell line.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10828833     DOI: 10.1677/jme.0.0240397

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  5 in total

1.  Somatostatin inhibits colon cancer cell growth through cyclooxygenase-2 downregulation.

Authors:  R Colucci; C Blandizzi; N Ghisu; T Florio; M Del Tacca
Journal:  Br J Pharmacol       Date:  2008-06-30       Impact factor: 8.739

Review 2.  Somatostatin receptors and their interest in diagnostic pathology.

Authors:  Marco Volante; Francesca Bozzalla-Cassione; Mauro Papotti
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

3.  Relationship between somatostatin receptor subtype expression and clinicopathology, Ki-67, Bcl-2 and p53 in colorectal cancer.

Authors:  Cheng-Zhi Qiu; Chuan Wang; Zhong-Xin Huang; Shi-Ze Zhu; You-Yi Wu; Jian-Long Qiu
Journal:  World J Gastroenterol       Date:  2006-04-07       Impact factor: 5.742

4.  Cellular detection of sst2A receptors in human gastrointestinal tissue.

Authors:  M Gugger; B Waser; A Kappeler; A Schonbrunn; J C Reubi
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

5.  Peptide receptor targeting in cancer: the somatostatin paradigm.

Authors:  Federica Barbieri; Adriana Bajetto; Alessandra Pattarozzi; Monica Gatti; Roberto Würth; Stefano Thellung; Alessandro Corsaro; Valentina Villa; Mario Nizzari; Tullio Florio
Journal:  Int J Pept       Date:  2013-02-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.